Trial Profile

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domvanalimab (Primary) ; Zimberelimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Nivolumab; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms STAR-221
Sponsors Arcus Biosciences; Taiho Pharmaceutical

21 Jul 2026 Planned End Date changed from 1 Jun 2026 to 1 Aug 2026.
21 Jul 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Aug 2026.
20 Apr 2026 According to Clinical Trials Information System trial is completed in Portugal, Hungry, Lithuania, Italy, France and Greece

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com